Edition: BP 2025 (Ph. Eur. 11.6 update)<\/p>\n
Action and use<\/strong><\/p>\n Co-enzyme in mitochondrial electron transport.<\/p>\n 2-[(all-E)-3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-5,6-dimethoxy-3- methylbenzene-1,4-dione.<\/p>\n Content<\/p>\n 98.0 per cent to 102.0 per cent (anhydrous substance).<\/p>\n Yellow or orange, hygroscopic, crystalline powder.<\/p>\n Practically insoluble in water, soluble in acetone, very slightly soluble in anhydrous ethanol. It gradually decomposes and darkens on exposure to light.<\/p>\n About 48 \u00b0C.<\/p>\n Carry out all operations protected from light.<\/p>\n A. Infrared absorption spectrophotometry (2.2.24).<\/p>\n Comparison\u00a0 ubidecarenone CRS.<\/p>\n B. Examine the chromatograms obtained in the assay.<\/p>\n Results The principal peak in the chromatogram obtained with the test solution is similar in retention time and size to the principal peak in the chromatogram obtained with reference solution (a).<\/p>\n Liquid chromatography (2.2.29). Carry out the test protected from light.<\/p>\n Test solution Dissolve 25.0 mg of the substance to be examined in 25.0 mL of anhydrous ethanol R by heating at about 50 \u00b0C for 2 min. Allow to cool.<\/p>\n Reference solution (a) Dissolve 25.0 mg of ubidecarenone CRS in 25.0 mL of anhydrous ethanol R by heating at about 50 \u00b0C for 2 min. Allow to cool.<\/p>\n Reference solution (b) Dissolve 2 mg of ubidecarenone impurity D CRS in 2.0 mL of the test solution by heating at about 50 \u00b0C for 2 min. Allow to cool. Dilute 1.0 mL of this solution to 50.0 mL with anhydrous ethanol R.<\/p>\n Reference solution (c) Dilute 1.0 mL of the test solution to 100.0 mL with anhydrous ethanol R. Dilute 5.0 mL of this solution to 10.0 mL with anhydrous ethanol R.<\/p>\n Column:<\/p>\n \u2014 size: l = 0.2 m, \u00d8 = 4.6 mm;<\/p>\n \u2014 stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 \u00b5m);<\/p>\n \u2014 temperature: 30 \u00b0C.<\/p>\n Mobile phase anhydrous ethanol R, methanol R2 (20:80 V\/V). Flow rate 1.7 mL\/min.<\/p>\n Detection\u00a0 Spectrophotometer at 275 nm.<\/p>\n Injection\u00a0 10 \u00b5L of the test solution and reference solutions (b) and (c).<\/p>\n Run time\u00a0 Twice the retention time of ubidecarenone.<\/p>\n Identification of impurities Use the chromatogram obtained with reference solution (b) to identify the peak due to impurity D.<\/p>\n Relative retention\u00a0 With reference to ubidecarenone (retention time = about 14 min): impurity D = about 0.7.<\/p>\n System suitability\u00a0 Reference solution (b):<\/p>\n \u2014 resolution: minimum 6.5 between the peaks due to impurity D and ubidecarenone.<\/p>\n Calculation of percentage contents:<\/p>\n \u2014 for each impurity, use the concentration of ubidecarenone in reference solution (c).<\/p>\n Limits:<\/p>\n \u2014 impurity D: maximum 0.3 per cent;<\/p>\n \u2014 unspecified impurities: for each impurity, maximum 0.10 per cent;<\/p>\n \u2014 total: maximum 0.6 per cent,<\/p>\n \u2014 reporting threshold: 0.05 per cent.<\/p>\n Liquid chromatography (2.2.29). Carry out the test protected from light.<\/p>\n Test solution\u00a0 Dissolve 25.0 mg of the substance to be examined in 25.0 mL of hexane R.<\/p>\n Reference solution (a) Dissolve the contents of a vial of ubidecarenone for system suitability CRS (containing impurity F) in 1.0 mL of hexane R.<\/p>\n Reference solution (b) Dilute 1.0 mL of the test solution to 100.0 mL with hexane R. Column:<\/p>\n \u2014 size: l = 0.25 m, \u00d8 = 4.0 mm;<\/p>\n \u2014 stationary phase: silica gel for chromatography R (7 \u00b5m).<\/p>\n Mobile phase ethyl acetate R, hexane R (3:97 V\/V). Flow rate 2 mL\/min.<\/p>\n Detection\u00a0 Spectrophotometer at 275 nm.<\/p>\n Injection\u00a0 20 \u00b5L.<\/p>\n Run time\u00a0 1.2 times the retention time of ubidecarenone.<\/p>\n Identification of impurities Use the chromatogram supplied with ubidecarenone for system suitability CRS and the chromatogram obtained with reference solution (a) to identify the peak due to impurity F.<\/p>\n Relative retention\u00a0 With reference to ubidecarenone (retention time = about 10 min): impurity F = about 0.85.<\/p>\n System suitability\u00a0 Reference solution (a):<\/p>\n \u2014 resolution: minimum 1.5 between the peaks due to impurity F and ubidecarenone.<\/p>\n Limit:<\/p>\n \u2014 impurity F: not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent).<\/p>\n Water (2.5.12)<\/strong><\/p>\n Maximum 0.2 per cent, determined on 3.00 g.<\/p>\n Sulfated ash (2.4.14)<\/strong><\/p>\n Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.<\/p>\n Injection\u00a0 Test solution and reference solution (a).<\/p>\n Calculate the percentage content of C59<\/sub>H90<\/sub>O4<\/sub> taking into account the assigned content of ubidecarenone CRS.<\/p>\n In an airtight container, protected from light.<\/p>\n Specified impurities\u00a0 D, F.<\/em><\/p>\n Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use)\u00a0 A, B, C, E, G.<\/em><\/p>\n A. 2,3-dimethoxy-5-methylbenzene-1,4-diol,<\/p>\n B. 2-[(all-E)-3,7,11,15,19,23,27-heptamethyloctadocosa-2,6,10,14,18,22,26-heptaenyl]-5,6-dimethoxy-3-methylbenzene- 1,4-dione (ubiquinone-7),<\/p>\n C. 5,6-dimethoxy-3-methyl-2-[(all-E)-3,7,11,15,19,23,27,31-octamethyldotriaconta-2,6,10,14,18,22,26,30- octaenyl]benzene-1,4-dione (ubiquinone-8),<\/p>\n D. 5,6-dimethoxy-3-methyl-2-[(all-E)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34- nonaenyl]benzene-1,4-dione (ubiquinone-9),<\/p>\n E. (2RS)-7,8-dimethoxy-2,5-dimethyl-2-[(all-E)-4,8,12,16,20,24,28,32,36-nonamethylheptatriaconta- 3,7,11,15,19,23,27,31,35-nonaenyl]-2H-1-benzopyran-6-ol (ubicromenol),<\/p>\n F. 2-[(2Z,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-5,6-dimethoxy-3-methylbenzene-1,4-dione (ubidecarenone (Z)-isomer),<\/p>\n G. unknown structure.<\/p>\n","protected":false},"excerpt":{"rendered":" Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Co-enzyme in mitochondrial electron transport. DEFINITION 2-[(all-E)-3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-5,6-dimethoxy-3- methylbenzene-1,4-dione. Content 98.0 per cent to 102.0 per cent (anhydrous substance). CHARACTERS Appearance Yellow or orange, hygroscopic, crystalline powder. Solubility Practically insoluble in water, soluble in acetone, very slightly soluble in anhydrous ethanol. It gradually decomposes and darkens…<\/p>\n","protected":false},"author":5,"featured_media":30808,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-30807","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/30807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=30807"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/30807\/revisions"}],"predecessor-version":[{"id":30811,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/30807\/revisions\/30811"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/30808"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=30807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=30807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=30807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}DEFINITION<\/h2>\n
CHARACTERS<\/h2>\n
Appearance<\/h3>\n
Solubility<\/h3>\n
mp<\/h3>\n
IDENTIFICATION<\/h2>\n
TESTS<\/h2>\n
Related substances<\/h3>\n
Impurity F<\/h3>\n
ASSAY<\/h2>\n
STORAGE<\/h2>\n
IMPURITIES<\/h2>\n